Brown Fat Activity and White Fat Accumulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vicente Gilsanz, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT01517581
First received: January 20, 2012
Last updated: January 24, 2012
Last verified: January 2012
  Purpose

White and brown adipocytes differ in their expression of hormones, cytokines, and inflammatory factors, and they modulate different biological functions. While white adipose tissue (WAT) serves as the primary site of energy storage, brown adipose tissue (BAT) instead metabolizes fat to produce heat and regulate body temperature. BAT is likely present in all humans, but the low prevalence of BAT depiction in adults and elderly subjects has hindered longitudinal assessments of the relation between BAT activity and WAT. Under typical imaging conditions, BAT is detected more frequently in children and teenagers than in adults with malignancy. Since most children with cancer have significantly shorter treatment courses and greater survival rates compared to adult patients, the investigators have the ability to examine the relation of repeated measures of body composition and BAT by selecting pediatric patients. In this study, the investigators will longitudinally examine whether BAT activity is related to changes in weight and the amounts of SAT, VAT, and abdominal muscle in children successfully treated for pediatric cancer.


Condition
Hodgkins Lymphoma
Non-hodgkins Lymphoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Study on the Association Between Brown Adipose Tissue Activation and White Adipose Tissue Accumulation in Successfully Treated Pediatric Malignancy

Resource links provided by NLM:


Further study details as provided by Children's Hospital Los Angeles:

Primary Outcome Measures:
  • Change from Baseline in Subcutaneous Adipose Tissue Volume at Follow-up [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
  • Change from Baseline in Visceral Adipose Tissue Volume at Follow-up [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
  • Change from Baseline in Presence of Brown Adipose Tissue [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
  • Change from Baseline in Abdominal Musculature Volume [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in Anthropometric Measures at Follow-up [ Time Frame: Baseline and up to 1 year ] [ Designated as safety issue: No ]
    Age, height, weight and BMI


Enrollment: 32
Study Start Date: October 2008
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Malignant Disease with no visualized BAT
Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.

  Eligibility

Ages Eligible for Study:   6 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pediatric patients with a history of malignancy such that they are required to undergo PET/CT exams.

Criteria

Inclusion Criteria:

  • Patients had PET/CT scans with evidence of malignant disease
  • Patients had no metabolically active BAT at diagnosis on their PET/CT scan
  • Patients were disease free within 1 year of diagnosis

Exclusion Criteria:

  • Patients had PET/CT scans with no evidence of malignant disease
  • Patients with metabolically active BAT at diagnosis on their PET/CT scan
  • Patients were not disease free within 1 year of diagnosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01517581

Locations
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027-6062
Sponsors and Collaborators
Children's Hospital Los Angeles
Investigators
Principal Investigator: Vicente Gilsanz, MD, PhD Children's Hospital Los Angeles
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Vicente Gilsanz, Professor, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier: NCT01517581     History of Changes
Other Study ID Numbers: CHLA-Gilsanz-BAT/WAT
Study First Received: January 20, 2012
Last Updated: January 24, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Hospital Los Angeles:
Brown adipose tissue

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on September 16, 2014